Aryn M. Rowsam
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Aryn M. Rowsam has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Dominic Smiraglia
Department of Cell Stress Biology, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA
24 shared publications - Hayley C. Affronti
Department of Cancer Biology, University of Pennsylvania, Philadelphia, Pennsylvania, USA
23 shared publications - Justine J. Jacobi
Department of Urology, Roswell Park Comprehensive Cancer Center, Buffalo, USA
23 shared publications - Mark D. Long
Department of Biostatistics and Bioinformatics, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA
23 shared publications - Spencer R. Rosario
Department of Biostatistics and Bioinformatics, Roswell Park Comprehensive Cancer Center, Buffalo, NY
23 shared publications - Hervé Tettelin
Department of Microbiology and Immunology, Institute for Genome Sciences, University of Maryland School of Medicine, Baltimore, USA
1 shared publication
Latest Publications
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Data from JAZF1: A Metabolic Regulator of Sensitivity to a Polyamine-Targeted Therapy
Identifying and leveraging unique points of metabolic dysregulation in different disease settings is vital for safe and effective incorporation of metabolism-targeted therapies in the clinic. In addition, it has been shown identification of master metabolic transcriptional regulators (MMTR) of individual metabolic pathways, and how they relate to the disease in question, may offer the key to understanding therapeutic response. In prostate cancer, we have previously demonstrated polyamine biosynthesis and the methionine cycle were targetable metabolic vulnerabilities. However, the MMTRs of these pathways, and how they affect treatment, have yet to be explored. We sought to characterize differential sensitivity of prostate cancer to polyamine- and methionine-targeted therapies by identifying novel MMTRs. We began by developing a gene signature from patient samples, which can predict response to metabolic therapy, and further uncovered a MMTR, JAZF1. We characterized the effects of JAZF1 overexpression on prostate cancer cells, basally and in the context of treatment, by assessing mRNA levels, proliferation, colony formation capability, and key metabolic processes. Lastly, we confirmed the relevance of our findings in large publicly available cohorts of prostate cancer patient samples. We demonstrated differential sensitivity to polyamine and methionine therapies and identified JAZF1 as a MMTR of this response.Implications:We have shown JAZF1 can alter sensitivity of cells and its expression can segregate patient populations into those that do, or do not highly express polyamine genes, leading to better prediction of response to a polyamine targeting therapy.
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from JAZF1: A Metabolic Regulator of Sensitivity to a Polyamine-Targeted Therapy
Identifying and leveraging unique points of metabolic dysregulation in different disease settings is vital for safe and effective incorporation of metabolism-targeted therapies in the clinic. In addition, it has been shown identification of master metabolic transcriptional regulators (MMTR) of individual metabolic pathways, and how they relate to the disease in question, may offer the key to understanding therapeutic response. In prostate cancer, we have previously demonstrated polyamine biosynthesis and the methionine cycle were targetable metabolic vulnerabilities. However, the MMTRs of these pathways, and how they affect treatment, have yet to be explored. We sought to characterize differential sensitivity of prostate cancer to polyamine- and methionine-targeted therapies by identifying novel MMTRs. We began by developing a gene signature from patient samples, which can predict response to metabolic therapy, and further uncovered a MMTR, JAZF1. We characterized the effects of JAZF1 overexpression on prostate cancer cells, basally and in the context of treatment, by assessing mRNA levels, proliferation, colony formation capability, and key metabolic processes. Lastly, we confirmed the relevance of our findings in large publicly available cohorts of prostate cancer patient samples. We demonstrated differential sensitivity to polyamine and methionine therapies and identified JAZF1 as a MMTR of this response.Implications:We have shown JAZF1 can alter sensitivity of cells and its expression can segregate patient populations into those that do, or do not highly express polyamine genes, leading to better prediction of response to a polyamine targeting therapy.
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Table from JAZF1: A Metabolic Regulator of Sensitivity to a Polyamine-Targeted Therapy
Supplementary Table from JAZF1: A Metabolic Regulator of Sensitivity to a Polyamine-Targeted Therapy
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table from JAZF1: A Metabolic Regulator of Sensitivity to a Polyamine-Targeted Therapy
Supplementary Table from JAZF1: A Metabolic Regulator of Sensitivity to a Polyamine-Targeted Therapy
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure from JAZF1: A Metabolic Regulator of Sensitivity to a Polyamine-Targeted Therapy
Supplementary Figure from JAZF1: A Metabolic Regulator of Sensitivity to a Polyamine-Targeted Therapy
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure from JAZF1: A Metabolic Regulator of Sensitivity to a Polyamine-Targeted Therapy
Supplementary Figure from JAZF1: A Metabolic Regulator of Sensitivity to a Polyamine-Targeted Therapy
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure from JAZF1: A Metabolic Regulator of Sensitivity to a Polyamine-Targeted Therapy
Supplementary Figure from JAZF1: A Metabolic Regulator of Sensitivity to a Polyamine-Targeted Therapy
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure from JAZF1: A Metabolic Regulator of Sensitivity to a Polyamine-Targeted Therapy
Supplementary Figure from JAZF1: A Metabolic Regulator of Sensitivity to a Polyamine-Targeted Therapy
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure from JAZF1: A Metabolic Regulator of Sensitivity to a Polyamine-Targeted Therapy
Supplementary Figure from JAZF1: A Metabolic Regulator of Sensitivity to a Polyamine-Targeted Therapy
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure from JAZF1: A Metabolic Regulator of Sensitivity to a Polyamine-Targeted Therapy
Supplementary Figure from JAZF1: A Metabolic Regulator of Sensitivity to a Polyamine-Targeted Therapy
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure from JAZF1: A Metabolic Regulator of Sensitivity to a Polyamine-Targeted Therapy
Supplementary Figure from JAZF1: A Metabolic Regulator of Sensitivity to a Polyamine-Targeted Therapy
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure from JAZF1: A Metabolic Regulator of Sensitivity to a Polyamine-Targeted Therapy
Supplementary Figure from JAZF1: A Metabolic Regulator of Sensitivity to a Polyamine-Targeted Therapy
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure from JAZF1: A Metabolic Regulator of Sensitivity to a Polyamine-Targeted Therapy
Supplementary Figure from JAZF1: A Metabolic Regulator of Sensitivity to a Polyamine-Targeted Therapy
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure from JAZF1: A Metabolic Regulator of Sensitivity to a Polyamine-Targeted Therapy
Supplementary Figure from JAZF1: A Metabolic Regulator of Sensitivity to a Polyamine-Targeted Therapy
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure from JAZF1: A Metabolic Regulator of Sensitivity to a Polyamine-Targeted Therapy
Supplementary Figure from JAZF1: A Metabolic Regulator of Sensitivity to a Polyamine-Targeted Therapy
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure from JAZF1: A Metabolic Regulator of Sensitivity to a Polyamine-Targeted Therapy
Supplementary Figure from JAZF1: A Metabolic Regulator of Sensitivity to a Polyamine-Targeted Therapy
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure from JAZF1: A Metabolic Regulator of Sensitivity to a Polyamine-Targeted Therapy
Supplementary Figure from JAZF1: A Metabolic Regulator of Sensitivity to a Polyamine-Targeted Therapy
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure from JAZF1: A Metabolic Regulator of Sensitivity to a Polyamine-Targeted Therapy
Supplementary Figure from JAZF1: A Metabolic Regulator of Sensitivity to a Polyamine-Targeted Therapy
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure from JAZF1: A Metabolic Regulator of Sensitivity to a Polyamine-Targeted Therapy
Supplementary Figure from JAZF1: A Metabolic Regulator of Sensitivity to a Polyamine-Targeted Therapy
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure from JAZF1: A Metabolic Regulator of Sensitivity to a Polyamine-Targeted Therapy
Supplementary Figure from JAZF1: A Metabolic Regulator of Sensitivity to a Polyamine-Targeted Therapy